Survodutide
Also known as BI 456906
Survodutide is an experimental weekly injection targeting GLP-1 and glucagon, being tested for obesity and fatty-liver disease (MASH).
How one dose clears
modeled over ~6 half-lives- Half-life
- 6.3 days
- Reported range
- 6.0 days–7.0 days
- Time to peak (Tmax)
- 24 h
- Steady state
- ~35 days
- Typical dose
- 0.6 mg
Investigational GLP-1 / glucagon receptor dual agonist for obesity and MASH. Once-weekly subcutaneous injection.
Mechanism of action
Albumin-bound dual agonist combining GLP-1 appetite/insulin effects with glucagon-driven energy expenditure.
Investigational — not FDA approved. Half-life is approximate (~6–7 days from early-phase data); titrate weekly.
References
Track Survodutide for free
Log your doses and PeptideBuddy models Survodutide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking freeFree. No card required.